Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $80.3333.
A number of equities research analysts have recently issued reports on TECX shares. Lifesci Capital initiated coverage on shares of Tectonic Therapeutic in a research report on Friday, June 6th. They issued an "outperform" rating and a $87.00 target price for the company. Wall Street Zen cut shares of Tectonic Therapeutic from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. Raymond James Financial assumed coverage on shares of Tectonic Therapeutic in a research report on Wednesday, June 11th. They set an "outperform" rating and a $76.00 price objective for the company. Mizuho upped their price objective on shares of Tectonic Therapeutic from $51.00 to $85.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Finally, Truist Financial assumed coverage on shares of Tectonic Therapeutic in a research report on Monday, July 21st. They set a "buy" rating and a $64.00 price objective for the company.
View Our Latest Report on Tectonic Therapeutic
Tectonic Therapeutic Stock Performance
Shares of Tectonic Therapeutic stock opened at $25.40 on Friday. The firm has a 50-day moving average of $21.84 and a 200-day moving average of $22.70. The stock has a market cap of $475.23 million, a PE ratio of -6.29 and a beta of 3.27. Tectonic Therapeutic has a 52-week low of $13.70 and a 52-week high of $61.07.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.09). Equities research analysts predict that Tectonic Therapeutic will post -8.31 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tectonic Therapeutic
Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in Tectonic Therapeutic during the fourth quarter worth about $1,329,000. Jane Street Group LLC bought a new position in shares of Tectonic Therapeutic in the fourth quarter worth about $1,371,000. Ameriprise Financial Inc. bought a new position in shares of Tectonic Therapeutic in the fourth quarter worth about $347,000. Barclays PLC lifted its holdings in shares of Tectonic Therapeutic by 1,008.5% in the fourth quarter. Barclays PLC now owns 15,974 shares of the company's stock worth $737,000 after acquiring an additional 14,533 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Tectonic Therapeutic in the fourth quarter worth about $228,000. Institutional investors own 62.63% of the company's stock.
About Tectonic Therapeutic
(
Get Free Report)
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tectonic Therapeutic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.
While Tectonic Therapeutic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access